Matthew Goetz
Overview
Explore the profile of Matthew Goetz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takchi A, Zhang M, Jalalirad M, Ferre R, Shrestha R, Haddad T, et al.
Front Oncol
. 2024 Jun;
14:1384277.
PMID: 38873259
Triple negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and mainly affects pre-menopausal and minority women. Because of the lack of ER, PR or HER2 expression in...
2.
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, et al.
J Clin Oncol
. 2023 Aug;
41(33):5118-5130.
PMID: 37556775
Purpose: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of...
3.
Ives J, Bagchi S, Soo S, Barrow C, Akgun K, Erlandson K, et al.
Contemp Clin Trials
. 2023 Jul;
132:107303.
PMID: 37481201
Chronic obstructive pulmonary disease (COPD) is one of the most common comorbid diseases among aging people with HIV (PWH) and is often mismanaged. To address this gap, we are conducting...
4.
Economos E, Goedken C, Hockett Sherlock S, Suda K, Goetz M, Balkenende E, et al.
Antimicrob Steward Healthc Epidemiol
. 2022 Dec;
2(1):e99.
PMID: 36483404
To investigate factors that influence antibiotic prescribing decisions, we interviewed 49 antibiotic stewardship champions and stakeholders across 15 hospitals. We conducted thematic analysis and subcoding of decisional factors. We identified...
5.
Mayer E, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein H, Zdenkowski N, et al.
J Clin Oncol
. 2022 Jan;
40(5):449-458.
PMID: 34995105
Purpose: The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human...
6.
Rugo H, Huober J, Garcia-Saenz J, Masuda N, Sohn J, Andre V, et al.
Oncologist
. 2021 Apr;
26(7):e1286-e1287.
PMID: 33826783
No abstract available.
7.
Rugo H, Huober J, Garcia-Saenz J, Masuda N, Sohn J, Andre V, et al.
Oncologist
. 2021 Mar;
26(3):e522.
PMID: 33660385
No abstract available.
8.
Mayer E, Dueck A, Martin M, Rubovszky G, Burstein H, Bellet-Ezquerra M, et al.
Lancet Oncol
. 2021 Jan;
22(2):212-222.
PMID: 33460574
Background: Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib to...
9.
Rugo H, Huober J, Garcia-Saenz J, Masuda N, Sohn J, Andre V, et al.
Oncologist
. 2020 Sep;
26(1):e53-e65.
PMID: 32955138
Background: Abemaciclib demonstrated efficacy in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Here we provide a comprehensive summary of the most common adverse events (AEs), their...
10.
Sigel K, Stone K, Wisnivesky J, Park L, Kong C, Silverberg M, et al.
AIDS
. 2019 Mar;
33(8):1353-1360.
PMID: 30889013
Objective: Lung cancer is the leading cause of cancer death in people living with HIV (PWH). Surgical resection is a key component of potentially curative treatment regimens for early-stage lung...